Cedric Francois, Chief Executive Officer at Apellis Pharmaceuticals, Inc. (APLS), sold 39,450 shares at $20.21 ($797K) on 2025-07-17, disclosed to the SEC on 2025-07-18.
Scheduled sale ($797k) by Chief Executive Officer under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $20.21 | 19,725 | $399K | 50.0% |
| 2 | $20.21 | 19,725 | $399K | 50.0% |
| Total | $20.21 avg | 39,450 | $797K | 100% |
| Filing → |
| APLS | SELL | 2026-01-15 | $226K | — | Filing → |
| APLS | SELL | 2025-08-29 | $12.7M | — | Filing → |
| APLS | SELL | 2025-07-16 | $5.6M | — | Filing → |